title: Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report.
abstract: Fourteen patients had primary ovarian lymphoma, while eighteen patients had secondary ovarian involvement. There was no significant difference in survival rates between primary and secondary involvement with diffuse large B-cell lymphoma (DLBCL), the most common subtype. The 5-year overall survivals of primary and secondary involvement with DLBCL were 70.0% and 59.3%, respectively. The localized bilateral ovarian involvement showed poorer survival compared to stage III/IV patients with secondary ovarian involvement. Treatment outcomes of secondary ovarian involvement in non-Hodgkin's lymphoma were comparable to those of primary ovarian involvement, suggesting that ovarian involvement does not necessarily predict a worse prognosis for NHL patients.
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, South Korea.
authors.forename: Jina
authors.initials: J
authors.lastname: Yun
authors.forename: Seok Jin
authors.initials: SJ
authors.lastname: Kim
authors.forename: Jong Ho
authors.initials: JH
authors.lastname: Won
authors.forename: Chul Won
authors.initials: CW
authors.lastname: Choi
authors.forename: Hyeon Seok
authors.initials: HS
authors.lastname: Eom
authors.forename: Jin Seok
authors.initials: JS
authors.lastname: Kim
authors.forename: Min Kyoung
authors.initials: MK
authors.lastname: Kim
authors.forename: Jae-Yong
authors.initials: JY
authors.lastname: Kwak
authors.forename: Won Seog
authors.initials: WS
authors.lastname: Kim
authors.forename: Cheolwon
authors.initials: C
authors.lastname: Suh
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000473:pathology / Q000556:secondary*; D011379:Prognosis; D012008:Recurrence; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult